Literature DB >> 8931589

Cerebral benzodiazepine receptors in hippocampal sclerosis. An objective in vivo analysis.

M J Koepp1, M P Richardson, D J Brooks, J B Poline, W Van Paesschen, K J Friston, J S Duncan.   

Abstract

We objectively delineated the extent of abnormalities in central benzodiazepine receptor (cBZR) binding using [11C]flumazenil (FMZ)-PET and high resolution volumetric MRI in 12 patients with mesial temporal lobe epilepsy (mTLE) associated with unilateral hippocampal sclerosis, who underwent presurgical evaluation and subsequent temporal lobe surgery. We compared parametric 3D-images of regional cerebral [11C]FMZ volume of distribution (Vd) obtained from individuals and groups of patients with [11C]FMZ-Vd from a group of 17 healthy controls using statistical parametric mapping (SPM). The [12C]FMZ-Vd was significantly reduced (P < 0.001) in the affected hippocampus in the group of 12 patients with unilateral hippocampal sclerosis. Analysis of individual patients reflected the group finding and there was no significant abnormality of cBZR binding outside the hippocampus in any patient. We conclude that SPM is an useful objective method for detecting changes in regional cerebral [11C]FMZ binding and that in patients with mTLE and unilateral hippocampal sclerosis reduction of cBZR binding is restricted to the area of hippocampal sclerosis with no abnormalities being detected in the temporal neocortex or elsewhere in the neocortex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931589     DOI: 10.1093/brain/119.5.1677

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  8 in total

1.  Implementation and application of a brain template for multiple volumes of interest.

Authors:  Alexander Hammers; Matthias J Koepp; Samantha L Free; Matthew Brett; Mark P Richardson; Claire Labbé; Vincent J Cunningham; David J Brooks; John Duncan
Journal:  Hum Brain Mapp       Date:  2002-03       Impact factor: 5.038

2.  The relationship between glucose metabolism, resting-state fMRI BOLD signal, and GABAA-binding potential: a preliminary study in healthy subjects and those with temporal lobe epilepsy.

Authors:  Allison C Nugent; Ashley Martinez; Alana D'Alfonso; Carlos A Zarate; William H Theodore
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

3.  Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy.

Authors:  F Loup; H G Wieser; Y Yonekawa; A Aguzzi; J M Fritschy
Journal:  J Neurosci       Date:  2000-07-15       Impact factor: 6.167

Review 4.  Advances in neuroimaging: management of partial epileptic syndromes.

Authors:  Barbara Schäuble; Gregory D Cascino
Journal:  Neurosurg Rev       Date:  2003-08-22       Impact factor: 3.042

Review 5.  Is central benzodiazepine receptor imaging useful for the identification of epileptogenic foci in localization-related epilepsies?

Authors:  Ingeborg Goethals; Christophe Van de Wiele; Paul Boon; Rudi Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-12-17       Impact factor: 9.236

6.  Application of statistical parametric mapping to SPET in the assessment of intractable childhood epilepsy.

Authors:  Jason M Bruggemann; Seu S Som; John A Lawson; Walter Haindl; Anne M Cunningham; Ann M E Bye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-28       Impact factor: 9.236

7.  Converging PET and fMRI evidence for a common area involved in human focal epilepsies.

Authors:  H Laufs; M P Richardson; A Salek-Haddadi; C Vollmar; J S Duncan; K Gale; L Lemieux; W Löscher; M J Koepp
Journal:  Neurology       Date:  2011-08-17       Impact factor: 9.910

8.  Αlpha 5 subunit-containing GABAA receptors in temporal lobe epilepsy with normal MRI.

Authors:  Colm J McGinnity; Daniela A Riaño Barros; Rainer Hinz; James F Myers; Siti N Yaakub; Charlotte Thyssen; Rolf A Heckemann; Jane de Tisi; John S Duncan; Josemir W Sander; Anne Lingford-Hughes; Matthias J Koepp; Alexander Hammers
Journal:  Brain Commun       Date:  2021-01-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.